Combined metabolic activators

Phase 3Small molecule

Combined metabolic activators is one of 61 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's DiseaseRecruiting

GoutNot yet recruiting

Alzheimer's DiseasePhase 3

Recruiting

GoutPhase 3

Not yet recruiting

Competition

Competitive Landscape

54 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

6 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Namenda

AbbVie

Phase 2

2 6

Leukine

Sanofi

Phase 2

1 7

Niacor

AbbVie

Phase 2

1 8

Briviact

UCB

Phase 2

1 9

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 10

Hytrin

AAbbott

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Not yet recruiting

Gout

NCT07889284

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Recruiting·SScandiBio Therapeutics AB·Phase 3·NCT07062198·845 enrolled

Gout1 trial

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

Not yet recruiting·SScandiBio Therapeutics AB·Phase 3·NCT07889284·336 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Combined metabolic activators. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combined metabolic activators compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combined metabolic activators. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ScandiBio Therapeutics AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SScandiBio Therapeutics AB

Combined metabolic activators

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Alzheimer's Disease1 trial

Gout1 trial

References

Drug Info

Quick Facts

Related News